Immunocore appoints Mohammed Dar

Mohammed will be responsible for clinical, operational, biostatistics and medical affairs functions across all therapeutic areas. This includes Immunocore’s wholly-owned lead programme, tebentafusp, in addition to the growing pipeline in oncology, infectious diseases, which includes target indications such as Hepatitis B and HIV, and autoimmune diseases.

“The potential of Immunocore’s unparalleled science and TCR platform is very impressive,” said Mohammed Dar. “I am thrilled to have joined Immunocore at such an exciting time for the Company and I look forward to working with the scientific leadership team to drive this compelling science forward.”